TMS Therapy is a revolutionary approach to treating various mental health disorders. It is crucial to understand patient eligibility requirements to benefit from this therapy. In this article, we will outline the essential criteria for patient eligibility and a roadmap for those seeking treatment. Understanding these requirements is the first step towards experiencing the therapeutic benefits of TMS, marking the beginning of a potentially life-changing journey for many.
Key Takeaways
- Eligibility for TMS therapy requires a diagnosis of moderate to severe major depressive disorder, previous unsuccessful treatment with at least two antidepressants and talk therapy, and a thorough medical and psychiatric evaluation considering factors like metal implants and seizure history.
- Deep TMS treatment is FDA-approved for a range of conditions, including depression1 and OCD2. It involves a personalized treatment protocol with brain mapping for each patient to ensure effective outcomes.
Eligibility Criteria for TMS Therapy
Transcranial magnetic stimulation (TMS) therapy offers a new horizon for individuals grappling with moderate to severe major depressive disorder, particularly for those who have seen little to no improvement with traditional treatment methods. Eligibility hinges on a confirmed diagnosis alongside a track record of unsuccessful attempts with standard treatments, including a minimum of two different antidepressant medications and psychotherapy.
Prior Treatment Attempts
The journey to TMS therapy often begins after a patient fails to respond to one or two antidepressant medication trials. It’s important to note that these unsuccessful attempts at treatment play a crucial role in determining whether TMS is an appropriate treatment option. This is because TMS treatment is primarily contemplated for patients who have shown resistance to standard treatments.
The severity of depression and the level of treatment resistance, such as in cases of pharmacoresistant major depressive disorder, are assessed through various factors, including depressive symptomatology and medication history. So, even though the road to TMS might be paved with unsuccessful treatment attempts for treatment-resistant patients, these prior experiences are vital in shaping the direction of your treatment journey.
Medical and Psychiatric Evaluation
Before starting TMS therapy, a comprehensive medical evaluation is essential. This evaluation includes physical exams, lab tests, and a mental health evaluation to ensure the patient’s safety and compatibility with the treatment. Certain factors, such as implanted medical devices, non-removable metallic objects in or around the head, or implants controlled by physiological signals, could pose risks due to the strong magnetic fields produced by the magnetic coil during treatment—all of which are checked during evaluation.
Besides physical health, healthcare providers also consider a patient’s psychiatric history. For instance, a history of seizures, severe headaches, traumatic brain injury, or a family history of epilepsy could impact the eligibility for TMS treatment. The goal is to ensure that TMS therapy is the right fit for the patient medically and psychiatrically.
Deep TMS at Plus by APN
At Plus by APN, deep brain stimulation treatments, also known as Deep TMS, are administered over six to eight weeks, each lasting approximately 20 minutes. This non-invasive treatment technique involves applying a magnetic field through magnetic pulses followed by a waiting period, known as intermittent theta burst stimulation3. This approach of Deep TMS primarily targets the dorsolateral prefrontal cortex (DLPFC), a region involved in mood regulation, decision-making, and focus. In depression, this area may be underactive. By utilizing brain stimulation, Deep TMS effectively targets the desired brain areas.
At Plus by APN, we offer Deep TMS treatment for:
- Depression
- OCD
- Anxious depression
- Aiding in smoking cessation
This wide range of applications underscores the versatility and potential of Deep TMS as a treatment option, offering hope to countless patients dealing with various mental health issues.
Clinical Outcomes with Deep TMS
Deep TMS has shown substantial efficacy in the treatment of major depression, with significant percentages of patients achieving clinical response and remission. In fact, 81.6% of patients treated for major depression with Deep TMS achieved a clinical response, while up to 65.3% of patients reached remission, according to Brainsway TMS data6.
But it’s not just about depression. Deep TMS has demonstrated over 52% positive response rate for obsessive-compulsive disorder after 29 treatments7, and has shown effectiveness in alleviating symptoms of anxious depression and aiding in smoking cessation. These impressive clinical outcomes underscore the potential of Deep TMS to change lives by providing relief for a range of mental health conditions.
The TMS Treatment Journey at Plus by APN
Consultation and Assessment
Prospective patients can schedule a complimentary initial consultation with Plus by APN by clicking here. This essential first step in the TMS treatment journey allows for an in-depth discussion of the patient’s psychiatric history and an evaluation of their suitability for TMS treatment. This assessment ensures a personalized and effective treatment plan, paving the way for the upcoming TMS treatment schedule.
The Treatment Schedule
The treatment schedule for TMS therapy at Plus by APN includes daily repeated sessions, with a duration of 20 minutes per day. This lasts for a typical six to eight-week acute phase, as per Plus by APN’s protocol for depression. Maintenance TMS therapyincludes sessions twice per week and is often necessary to sustain the benefits of the acute phase, particularly in treating depression.
Regular weekly adjustments, typically shorter than the initial motor threshold mapping, are carried out to recalibrate the TMS device, ensuring the treatment remains tailored and effective.
This comprehensive treatment schedule and personalized adjustments are a testament to Plus by APN’s commitment to delivering tailored and effective TMS therapy.
Frequently Asked Questions
What is TMS therapy, and who is eligible?
TMS therapy is an FDA-approved treatment for conditions like major unipolar depression, and obsessive-compulsive disorder (OCD). Eligibility requires a diagnosis of moderate to severe major depressive disorder and unsuccessful trials of at least two antidepressant medications and talk therapy.
How does Plus by APN approach TMS therapy?
Plus by APN’s approach TMS therapy by providing personalized treatment using brain mapping techniques and deep TMS sessions over a six to eight-week period, with sessions lasting about 20 minutes.
Does insurance cover TMS therapy?
Yes, Medicare and many private insurance companies generally cover TMS therapy for treating major depressive disorder, but specific coverage policies vary and often impose stringent criteria. It’s essential to check with your insurance provider for more details.
What are some complementary treatments to TMS therapy?
Complementary treatments to TMS therapy include ketamine therapy, prescribed medications, and psychotherapy for enhanced outcomes. Combining these treatments can be beneficial for overall effectiveness.
Final Thoughts
Transcranial magnetic stimulation (TMS) therapy emerges as a groundbreaking treatment for individuals grappling with mental health conditions such as major unipolar depression, OCD, anxious depression, and the challenge of smoking cessation. At Plus by APN, we personalize TMS therapy, tailoring it to effectively meet the unique needs of each patient. We meticulously guide patients through every phase of their TMS journey, covering eligibility criteria, treatment schedules, and insurance coverage.
We at Plus by APN dedicate ourselves to ensuring access to these cutting-edge treatments. It’s time to step into the future of mental health care—a future where treatments are not only personalized and effective but also infused with compassion. We invite you to book your free consultation today and join us in embracing this new era of mental health care.
References
- https://www.brainsway.com/treatments/major-depressive-disorder/
- https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorder
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10970838/
- https://www.brainsway.com/how-does-it-work/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699923/
- https://www.sciencedirect.com/science/article/pii/S0165178123001300
- https://pubmed.ncbi.nlm.nih.gov/33183769/